SANOFI US SERVICES INC.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$639.7M
Doctors Paid
1,430
Transactions
114,297
2024 Total
$113.9M
Payment Breakdown by Category
Research$629.9M (98.5%)
Consulting$5.3M (0.8%)
Travel$343,996 (0.1%)
Royalty/License$140,042 (0.0%)
Food & Beverage$60,029 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $629.9M | 110,738 | 98.5% |
| Consulting Fee | $5.3M | 1,299 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.5M | 549 | 0.6% |
| Travel and Lodging | $343,996 | 739 | 0.1% |
| Charitable Contribution | $263,161 | 317 | 0.0% |
| Royalty or License | $140,042 | 9 | 0.0% |
| Grant | $117,775 | 26 | 0.0% |
| Food and Beverage | $60,029 | 620 | 0.0% |
Payments by Type
Research
$629.9M
110,738 transactions
General
$9.8M
3,559 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis | $25.7M | 0 | 14 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who | $20.7M | 0 | 4,442 |
| Pooled Study for Isatuximab | $19.8M | 0 | 195 |
| The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study | $19.3M | 0 | 32 |
| Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | $14.5M | 1 | 1,804 |
| Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | $13.7M | 8 | 1,692 |
| Cabazitaxel with abiraterone acetate versus abiraterone acetate alone randomized trial for extensive disease following docetaxel: the CHAARTED2 trial | $11.6M | 0 | 9 |
| A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive P | $9.1M | 0 | 2,772 |
| REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | $8.0M | 0 | 64 |
| IST- Tolerance Combination Dose-Carfilzomide-IV | $7.1M | 0 | 122 |
| A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) | $6.7M | 0 | 249 |
| Asthma dupilumab | $6.5M | 6 | 1,218 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc | $6.1M | 0 | 1,313 |
| An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors | $6.0M | 0 | 614 |
| An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | $6.0M | 0 | 124 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | $5.9M | 0 | 1,639 |
| A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease | $5.9M | 0 | 1,097 |
| A Phase I Study of Mozobil in the Treatment of Patients with the Primary Immunodeficiency WHIM Syndrome | $5.9M | 0 | 9 |
| A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | $5.7M | 2 | 1,018 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk | $5.6M | 6 | 1,253 |
| A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers | $5.6M | 2 | 2,268 |
| IST-1L-Smoldering myeloma-PT- IV | $5.4M | 0 | 51 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently E | $5.4M | 0 | 2,680 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | $5.2M | 22 | 401 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | $5.2M | 3 | 1,599 |
| A Phase II follow-up study to determine whether the addition of whole brain radiotherapy (WBRT) to standard temozolomide chemo-radiotherapy will improve overall survival in patients with newly diagnos | $5.1M | 0 | 11 |
| Effect of DrOnedarone on atrial fibrosis progression and atrial fibrillation Recurrence post Ablation,The EDORA trial | $4.9M | 0 | 3 |
| Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | $4.8M | 1 | 580 |
| A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients with Type 2 Dia | $4.7M | 18 | 1,005 |
| A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma | $4.5M | 0 | 198 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Dr. Andres Patron, D.o, D.O | Internal Medicine | Pembroke Pines, FL | $738,496 | $0 |
| Dr. Lawrence Feld, M.d, M.D | Family Medicine | Gilbert, AZ | $310,082 | $0 |
| Dr. Hugh Windom, M.d, M.D | Allergy | Sarasota, FL | $266,520 | $0 |
| Dr. Deepak Bhatt, Md, MD | Cardiovascular Disease | New York, NY | $218,925 | $0 |
| Dr. Paul Shapero, Md, MD | Allergy & Immunology | Bangor, ME | $214,435 | $0 |
| Dr. Stephen Ong, Md, MD | Surgery | Oxon Hill, MD | $201,680 | $0 |
| Helena Rodbard, M.d, M.D | Endocrinology, Diabetes & Metabolism | Rockville, MD | $196,610 | $0 |
| Dr. Jeffrey Testani, M.d, M.D | Cardiovascular Disease | New Haven, CT | $194,070 | $0 |
| Dr. Ramesh Gupta, M.d, M.D | Specialist | Memphis, TN | $187,719 | $0 |
| Dr. Hal Roseman, M.d, M.D | Cardiovascular Disease | Nashville, TN | $159,784 | $0 |
| Dr. Michael Reeves, Md, MD | Specialist | Chattanooga, TN | $159,462 | $0 |
| Dr. Eric Nolen, Md, Mba, MD, MBA | Family Medicine | Houston, TX | $158,026 | $0 |
| Dr. Robert Truog, Md, MD | Anesthesiology | Boston, MA | $142,415 | $0 |
| Mr. Paul Norwood, M.d., F.a.c.p, M.D., F.A.C.P | Endocrinology, Diabetes & Metabolism | Fresno, CA | $141,357 | $0 |
| Dr. John Egan, M.d, M.D | Student in an Organized Health Care Education/Training Program | Minneapolis, MN | $125,615 | $0 |
| Leon Kircik, Md, MD | Dermatology | Lousiville, KY | $119,454 | $0 |
| Mr. John Ligeon, Md, MD | Internal Medicine | Orlando, FL | $104,427 | $0 |
| Joan Merrill, Md, MD | Rheumatology | Oklahoma City, OK | $101,019 | $0 |
| Dr. Jennifer Zomnir, M.d, M.D | Family Medicine | Frisco, TX | $98,337 | $0 |
| Dr. Ivan Mefford, Md, MD | Family Medicine | Richmond, TX | $97,204 | $0 |
| Bertram Pitt, Md, MD | Internal Medicine | Ann Arbor, MI | $93,127 | $0 |
| Dr. Steven Edelman, M.d, M.D | Internal Medicine | San Diego, CA | $88,611 | $0 |
| Dr. Mehran Kashefi, D.o, D.O | Internal Medicine | Los Angeles, CA | $86,145 | $0 |
| Pramod Mistry, Mbbs Phd, MBBS PHD | Gastroenterology | New Haven, CT | $82,391 | $0 |
| Roopen Patel, Md, MD | Allergy & Immunology | Charlotte, NC | $81,107 | $0 |
Ad
Top Products
- NO PRODUCT DISCUSSED $82.4M
- SARCLISA $49.7M
Associated Products (41)
- NO PRODUCT DISCUSSED $126.4M
- SARCLISA $69.6M
- JEVTANA $48.9M
- SAR439954 $42.0M
- MOZOBIL $40.5M
- LANTUS $28.2M
- REZUROCK $16.2M
- SAR439977 $14.3M
- GZ402666 $12.9M
- ADLYXIN $12.4M
- ISATUXIMAB $8.7M
- CLOLAR $4.6M
- SAR231893 $4.4M
- SOTAGLIFLOZIN $4.1M
- EFPEGLENATIDE $3.9M
- SAR341402 $3.7M
- SAR440340 $2.7M
- SAR439859 $1.3M
- SAR425899 $1.2M
- SAR439459 $991,482
- CIALIS $958,377
- SAR422459 $910,154
- SAR439794 $849,904
- SAR650984 $735,822
- SAR228810 $729,042
- FITUSIRAN $718,806
- SAR156597 $248,133
- SAR421869 $223,460
- SAR153191 $131,846
- PLAQUENIL $128,165
- SAR407899 $111,125
- SAR408701 $103,141
- SAR439483 $99,188
- SAR442085 $93,995
- SAR441169 $44,025
- SAR441000 $40,344
- SAR260301 $34,710
- SAR245409 $28,843
- SAR440234 $26,250
- SAR339375 $22,100
- AAV2-SFLT01 $17,729
Payment Categories
- Food & Beverage $60,029
- Consulting $5.3M
- Travel & Lodging $343,996
- Research $629.9M
- Royalties $140,042
About SANOFI US SERVICES INC.
SANOFI US SERVICES INC. has made $639.7M in payments to 1,430 healthcare providers, recorded across 114,297 transactions in the CMS Open Payments database. In 2024, the company paid $113.9M. The top product by payment volume is NO PRODUCT DISCUSSED ($82.4M).
Payments were distributed across 109 medical specialties. The top specialty by payment amount is Internal Medicine ($2.5M to 224 doctors).
Payment categories include: Food & Beverage ($60,029), Consulting ($5.3M), Research ($629.9M), Travel & Lodging ($343,996), Royalties ($140,042).
SANOFI US SERVICES INC. is associated with 41 products in the CMS Open Payments database, including NO PRODUCT DISCUSSED, SARCLISA, and JEVTANA.